What’s The Risk Of Myocarditis After mRNA-Based COVID-19 Vaccine?

Share

Tweet

Share

Share

Email

Comments

What is the risk of myocarditis after mRNA-based COVID-19 vaccination in the US as calculated from the underreported VEARS system?

These rates appear to be a little low and I am unsure how they were able to divide myocarditis post vaccination in 12 to 15 year old boys by vaccination type in 12 to 15 year old boys.

Someone found a way to identify these people from people of all ages. Maybe genomics?

The rates of myocarditis cases were highest after the second vaccination dose in adolescent males aged:

— 16 to 17 years (105.9 per million doses of the BNT162b2 vaccine)

— 12 to 15 years old (70.7 per million doses of the BNT162b2 vaccine)

— 18 to 24 years (52.4 and 56.3 per million doses of the BNT162b2 vaccine and the mRNA-1273 vaccine, respectively)

Conclusion

Based on passive surveillance reporting in the US, the risk of myocarditis after receiving mRNA-based COVID-19 vaccines was increased across multiple age and sex strata and was highest after the second vaccination dose in adolescent males and young men.